Compounds / DSIP
DSIP
Also known as: Delta Sleep-Inducing Peptide; Emideltide (FDA naming); WAGGDASGE; CAS 62568-57-4
Primary research focus: Sleep and neuromodulation research (delta-wave sleep, stress, circadian signaling)
Last updated July 2026 · Reviewed against FDA labeling and published research.
What is DSIP?
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), first isolated in the 1970s from the cerebral venous blood of sleeping rabbits. It has been studied for delta-wave sleep, stress resistance, and circadian signaling. It is a research compound with no regulatory approval; the FDA refers to it as Emideltide in 2026 compounding-review materials.
DSIP's mechanism is not well defined. It is an amphiphilic neuromodulatory peptide found in the hypothalamus, limbic system, and pituitary, and reported to influence delta-wave sleep architecture, neuroendocrine signaling (co-localizing with ACTH, TSH, and other mediators), and neurotransmitter activity; some studies implicate NMDA-receptor and adrenergic signaling. Notably, its gene and a specific receptor have not been identified, and later reviews concluded the sleep-factor hypothesis is weakly documented, with DSIP-like immunoreactivity possibly reflecting related peptides.
How it’s supplied
Not an FDA-approved or commercially manufactured medicine. It is sold as a research-grade lyophilized peptide (for example 5, 10, or 15 mg vials) for reconstitution. Research-grade products are not FDA-reviewed for potency or sterility.
Dosage Chart
Units shown are for a U-100 insulin syringe (100 units = 1 mL), calculated from the vial size and BAC water you select. Always confirm against your prescription and your syringe markings.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Weeks 1-2 | 100mcg | 1x Daily | — |
| Weeks 3-4 | 200mcg | 1x Daily | — |
| Weeks 5-8 | 300mcg | 1x Daily | — |
- Rotate injection sites to reduce irritation and lipohypertrophy
- Not for use during pregnancy or breastfeeding
- Do not exceed the recommended dose to try to speed results
- Typically administered at bedtime to align with natural melatonin rhythms
Potential Benefits and Side Effects
Effects reported in published research. Not a promise of results, and not medical advice.
- Reported in older, small human trials and preclinical research; not robustly established.
- Modulation of delta-wave sleep architecture without suppressing REM in some studies.
- Reported benefit in chronic insomnia and in opioid-withdrawal symptom management in small trials.
- Reported stress-protective, antiseizure, and antioxidant effects in animal models.
- Reported adverse effects in the small human trials were generally mild and infrequent.
- The overall human safety database is limited, so uncommon or long-term effects are not well characterized.
Warnings and contraindications
Important safety information. This is not exhaustive — read the full prescribing information and consult your prescriber or pharmacist.
- No FDA-approved labeling exists; the following reflect the compound's status and the limits of its evidence, not established label warnings.
- Human clinical trials were small, dated, and produced mixed results; the human safety and efficacy picture is not robust.
- The sleep-factor hypothesis is weakly documented, and measured DSIP-like material may reflect related peptides.
- Research-grade material varies in identity and purity.
- Safety in pregnancy and breastfeeding has not been established.
- Not established; no FDA-approved labeling. Precautionary considerations include known hypersensitivity to the peptide.
Reconstitution Steps
How to prepare the lyophilized vial. Confirm specifics with your pharmacist or prescriber.
- Confirm the amount of peptide in the vial and the volume of diluent you intend to use before starting.
- Wash your hands and gather supplies: the lyophilized vial, the diluent (typically bacteriostatic water), an alcohol swab, and a sterile syringe.
- Let the vial and diluent reach room temperature if they were refrigerated or frozen.
- Wipe the rubber stopper of both the peptide vial and the diluent vial with a fresh alcohol swab and let them air dry.
- Draw the intended diluent volume into the syringe.
- Insert the needle into the vial and slowly release the diluent down the inside wall rather than directly onto the powder, to avoid foaming.
- Do not shake. Gently swirl or roll the vial until fully dissolved.
- Inspect the solution: it should be clear and colorless with no visible particles. Do not use if cloudy or containing particles.
- Note the resulting concentration (amount divided by diluent volume) so it matches the reconstitution calculator on this page.
- Label the vial with the reconstitution date and store as directed under reconstituted storage.
US regulatory status
Classifications are public record but can change. For reference only, not legal advice.
Development: DSIP was discovered in the 1970s by the Schoenenberger-Monnier group in Switzerland. Over subsequent decades it was studied in a small number of human clinical trials (for chronic insomnia, opioid withdrawal, and chronic pain), with mixed results, and in preclinical models for stress protection, antiseizure, and geroprotective effects (including a phosphorylated derivative, Deltaran). No sponsor pursued it to approval. Under the FDA name Emideltide, DSIP (free base and acetate) is scheduled for discussion at the FDA Pharmacy Compounding Advisory Committee on July 24, 2026, where opioid withdrawal, chronic insomnia, and narcolepsy were among the reviewed uses. There is no FDA approval and no active IND as of mid-2026.
Notes: DSIP is not FDA-approved. Under the name Emideltide, it is part of the FDA's 2026 Pharmacy Compounding Advisory Committee review (July 24, 2026) for the 503A bulks list, so its compounding eligibility is under review and should be verified against the current FDA list. It is sold as a research-grade chemical, which is not FDA-reviewed for safety, potency, or sterility. It is not a controlled substance. (Status current as of mid-2026.)
International status
Pharmacokinetics
Storage and handling
Important Notes
Practical considerations for consistency and safety.
- The FDA refers to DSIP as Emideltide in its 2026 compounding-review materials.
- Its compounding status is under active FDA review (July 2026 advisory committee); verify the current classification.
- Human evidence is limited, dated, and mixed; the sleep-factor hypothesis is weakly documented.
- DSIP is unusual in that its gene and receptor remain unidentified.
- Research-grade material varies in identity and purity.
Lifestyle Factors
- Studied in the context of sleep and circadian rhythm; good sleep hygiene remains foundational for sleep concerns.
- Human lifestyle interactions beyond trial conditions are not well characterized.
References
Related compounds
Important disclaimer
This page is an educational reference, not medical advice, a diagnosis, or a treatment recommendation, and not a substitute for your prescriber or pharmacist. Approval and regulatory status varies by compound and can change. Always confirm against current prescribing information and consult a qualified healthcare professional before making any decision about a medication.